Barclays Initiates Quest Diagnostics With Equalweight

Loading...
Loading...
Analysts at Barclays initiated coverage on
Quest Diagnostics Inc.DGX
with a Equalweight rating, according to sources. The target price for Quest Diagnostics is set to $78. Quest Diagnostics shares have gained 33.91% over the past 52 weeks, while the S&P 500 index has surged 14.02% in the same period. Quest Diagnostics' shares fell 1.35% to close at $70.14 on Friday.
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: InitiationAnalyst RatingsBarclays
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...